Treating Stress with Wearable Technology

Can Wearable Technology Help Alleviate Stress?

, ,
Can wearable technology help alleviate stress? Apollo Neuro's new wearable shows amazing promise
Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

,
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.

Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More

This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and...
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

, ,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

,
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success...

Psychedelic Business Spotlight – June 10

,
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and...

Psychedelic Business Spotlight – June 3

,
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!

Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview

In today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA. ATMA is a company that is primarily focused on training therapists on how...
5 Next-Generation Psychedelics Entering Clinical Trials This YearShutterstock

5 Next-Generation Psychedelics Entering Clinical Trials This Year

,
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.